Simcere Pharmaceutical Group Limited announced resignation of Mr. Tang Renhong, from the position of the Co-CEO with effect from December 31, 2022 due to work rearrangement. Mr. Tang will focus on the overall leading of the business affairs of Simcere Zaiming, which is responsible for the research and development, production and marketing of oncology pharmaceuticals of the Group. Mr. Tang has confirmed that he has no disagreement with the Board and there is no matter in respect of his resignation as the Co-CEO that needs to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.21 HKD | +1.31% | +8.95% | -7.73% |
06-03 | Simcere Pharmaceutical’s Cancer Drug Shows Positive Results | MT |
06-03 | Simcere Pharma Presents Results of Phase 3 Trial for Anti-Cancer Injection at US Oncology Society Meeting | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-7.73% | 2B | |
+13.53% | 41.95B | |
+22.20% | 22.53B | |
+17.35% | 14.11B | |
+45.62% | 12.5B | |
-0.05% | 6.79B | |
-9.44% | 6.75B | |
-8.87% | 5.73B | |
+14.55% | 5.6B | |
+4.00% | 4.95B |
- Stock Market
- Equities
- 2096 Stock
- News Simcere Pharmaceutical Group Limited
- Simcere Pharmaceutical Group Limited Announces Resignation of Mr. Tang Renhong, from the Position of the Co-CEO with Effect from December 31, 2022